https://www.selleckchem.com/pr....oducts/brivudine.htm
Introduction Immunotherapy-related hepatitis accounts for 3-6% of all immune-related adverse events (irAE). Reintroduction of checkpoint inhibitors after irAE is matter of debate, weighing the risk of a relapse of adverse events against the possibility of improving disease control. Pharmacokinetic modelling has changed the paradigm of weight-based dosing to flat dose for checkpoint inhibitors, however, it is currently unknown if this poses underweight ( less then 80 kg) patients to a higher risk of toxicity. Weight-based dosing has be
Like
Comment
Share
